PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
about
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.HER3 and downstream pathways are involved in colonization of brain metastases from breast cancerα-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.Immune effects of trastuzumabLocal variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopyConditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutationsPIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metforminHER2-positive male breast cancer: an update.Cross-talk and modulation of signaling between somatostatin and growth factor receptors.Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers.Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
P2860
Q27851582-A30A2FEF-526A-49A6-B0AF-A3692E14FD26Q34173413-07DE75BD-1BA8-458E-ADB9-D4A451C0B70BQ34577504-B38E3E03-20E9-45B2-9E07-197E0F497950Q34664129-F4EEFB59-908A-447A-B2D6-03C2FA04EEC1Q35024073-CE355B32-CCF3-495B-BBE2-DE8AECC410DCQ35057976-C104458F-4C6C-422D-BAEF-D7574A81D548Q36284765-0A1AC7BC-A2AD-4774-BAAD-DA3A347AA830Q36549790-152DC0B3-6C32-4B09-8516-59D92A56CC57Q36978609-81E3A231-0AFC-4EE3-8099-5D379CE8DF21Q37299288-447756F5-07DC-405D-823E-BB12D468F29CQ37355586-656BC2B4-E617-4C08-A0A3-72B51E7B2A0DQ37922648-FD939431-F2C5-4EA4-837A-ADD43516DCAEQ38695293-27C09328-0143-4603-8D0A-E783484E19B1Q38980249-E7ED983A-46B8-40F1-B117-D302E1060AD3
P2860
PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@en
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@nl
type
label
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@en
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@nl
prefLabel
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@en
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@nl
P1433
P1476
PI3K inhibition overcomes tras ...... B2/ErbB3 is not always enough.
@en
P2093
Julien H Dey
Nancy E Hynes
P304
P356
10.1016/J.CCR.2009.04.004
P577
2009-05-01T00:00:00Z